As of September 30, 2026, MedCap AB carries a market capitalization of 691.58M, placing it among publicly traded companies globally. Its enterprise value stands at 706.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 691.58M |
| Enterprise Value | 706.28M |
MedCap AB's next confirmed earnings release is scheduled for February 5, 2027.
| Earnings Date | 2/5/2027 |
As of September 30, 2026, MedCap AB has 14.98M shares outstanding.
| Shares Outstanding | 14.98M |
As of September 30, 2026, MedCap AB trades at a trailing price-to-earnings ratio of 28.60. The price-to-sales ratio is 3.38, and the price-to-book ratio stands at 4.59.
| PE Ratio | 28.60 |
| PS Ratio | 3.38 |
| PB Ratio | 4.59 |
| P/TBV Ratio | 24.99 |
| P/FCF Ratio | 22.22 |
| P/OCF Ratio | 18.59 |
As of September 30, 2026, MedCap AB trades at an EV/EBITDA multiple of 13.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. MedCap AB trades at an EV/FCF ratio of 19.93, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 706.28M versus a market cap of 691.58M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 3.45 |
| EV / EBITDA | 13.61 |
| EV / EBIT | 19.96 |
| EV / FCF | 19.93 |
As of September 30, 2026, MedCap AB maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.60, indicating elevated leverage, while an interest coverage ratio of 9.49 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.71 |
| Quick Ratio | 0.45 |
| Debt / Equity | 25.60 |
| Debt / EBITDA | 0.74 |
| Interest Coverage | 9.49 |
Over the twelve months ended September 30, 2026, MedCap AB posted a return on equity (ROE) of 17.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.76 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.23, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.76, useful for judging operating efficiency across full business cycles. The company generates approximately 321,423.46 in revenue per employee across its workforce of 637.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.00 indicates how many times MedCap AB sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 17.91 |
| Return on Assets (ROA) | 11.23 |
| Return on Invested Capital (ROIC) | 15.76 |
| Return on Capital Employed (ROCE) | 16.76 |
| Revenue Per Employee | 321,423.46 |
| Employee Count | 637.00 |
| Inventory Turnover | 3.00 |
Over the twelve months ended September 30, 2026, MedCap AB recorded 6.83M in income tax expense. That works out to an effective tax rate of 21.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 31.08M, leaving 24.21M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 6.83M |
| Effective Tax Rate | 21.97 |
As of the close on November 17, 2026, MedCap AB's stock has gained approximately 2.87% over the past 52 weeks. The 50-day moving average sits at 48.20, while the 200-day moving average is 47.31.
| 52-Week Price Change | 2.87% |
| 50-Day Moving Average | 48.20 |
| 200-Day Moving Average | 47.31 |
Over the twelve months ended September 30, 2026, MedCap AB generated 204.75M in revenue and converted that into 24.21M in net income, yielding earnings per share of 1.62. EBITDA reached 51.89M, while operating income came in at 35.40M.
| Revenue | 204.75M |
| Gross Profit | 122.04M |
| Operating Income | 35.40M |
| Pretax Income | 31.08M |
| Net Income | 24.21M |
| EBITDA | 51.89M |
| EBIT | 35.39M |
| Earnings Per Share (EPS) | 1.62 |
As of September 30, 2026, MedCap AB holds 24.07M in cash and equivalents against 38.62M in total debt, resulting in a net debt position of -6.93M. Total book value stands at 150.67M, with working capital of 37.40M providing operational flexibility.
| Cash & Cash Equivalents | 24.07M |
| Total Debt | 38.62M |
| Net Debt | -6.93M |
| Equity (Book Value) | 150.67M |
| Book Value Per Share | 10.06 |
| Working Capital | 37.40M |
MedCap AB produced 37.23M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.07M in capital expenditures, free cash flow totaled 31.16M - equivalent to 2.08 per share.
| Operating Cash Flow | 37.23M |
| Capital Expenditures | -6.07M |
| Free Cash Flow | 31.16M |
| FCF Per Share | 2.08 |
Over the twelve months ended September 30, 2026, MedCap AB posted a gross margin of 59.61, reflecting its pricing power and cost economics. The operating margin of 17.29 and net profit margin of 11.82 provide insight into operational efficiency.
| Gross Margin | 59.61 |
| Operating Margin | 17.29 |
| Pretax Margin | 15.18 |
| Profit Margin | 11.82 |
| EBITDA Margin | 25.34 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 4.50, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MedCap AB shareholders.
| Shareholder Yield | 2.84 |
| FCF Yield | 4.50 |
MedCap AB's most recent stock split took place on September 27, 2016 with a 10:1 split ratio.
| Last Split Date | 9/27/2016 |
| Split Ratio | 10:1 |
Already premium?